#USA #Grand Rapids #cultivate(MD) #SPDx #Instrumentum

cultivate(MD) Announces Acquisition of SPDx by Instrumentum

In a significant development in the healthcare space, cultivate(MD), a prominent venture capital firm focused on medical devices, has announced its acquisition of Sterile Processing Express (SPDx) by Instrumentum, a rapidly growing entity specializing in surgical instrument sterilization services. This strategic move, revealed on June 11, 2025, promises to enhance the operational capabilities and service reach of Instrumentum in a competitive market.

The acquisition facilitates the expansion of Instrumentum’s operations to five facilities across four states, illustrating a calculated response to the burgeoning demand for offsite sterile processing services. This demand is largely driven by a notable increase in elective surgeries being performed at hospitals, clinics, and ambulatory surgery centers (ASCs). Such expansions not only elevate operational capacity but also solidify the importance of sterile services in ensuring patient safety and surgical efficacy.

David Blue, Director at cultivate(MD) and a member of the SPDx board, expressed his enthusiasm about the merger. He noted, "SPDx could not be more excited to see this relationship and partnership come together with Instrumentum. We saw this vision early on many years ago, recognizing the immense value this would bring to both ASCs and hospitals. These are indeed exciting times ahead!"

This acquisition marks a pivotal success for SPDx's sterile processing model and affirms cultivate(MD)’s initial investment vision. The integration of SPDx's operations into Instrumentum will create a scalable commercial platform that is poised for aggressive nationwide expansion. As stated by Matt Ahearn, another Director at cultivate(MD) and Chairman of SPDx, "This transaction represents a strategic move that enables us to integrate the facility launch, quality, and operational expertise of SPDx with the commercial strategy of Instrumentum. We believe this collaboration will maximize the potential of this market opportunity."

The implications of this merger extend beyond operational advantages. It signals cultivate(MD)’s commitment to identifying and nurturing innovative healthcare solutions that promise significant returns and positive clinical outcomes. By focusing on cutting-edge technologies, cultivate(MD) remains dedicated to its mission of transforming healthcare delivery and enhancing patient care.

Instrumentum, the acquirer in this merger, is rapidly positioning itself as a leader in the surgical sterilization industry, catering to outpatient surgery centers and hospitals alike. Their mission is clear: to become the most trusted provider of medical device sterilization services. With its headquarters and first operational facility located in Florida, Instrumentum has expanded to include facilities in Chicago, Phoenix, Long Beach, and Modesto, with plans for further expansions in the upcoming years.

The recent acquisition underscores the essential role of collaboration in the medical device sector. As the demand for reliable and efficient surgical services continues to grow, partnerships like the one between cultivate(MD), SPDx, and Instrumentum will be crucial in addressing the healthcare challenges of today.

While the statement includes a caution regarding forward-looking statements, the optimism surrounding this acquisition is palpable among stakeholders. As cultivation(MD) continues to advance in its mission to elevate healthcare standards, both patients and healthcare providers can anticipate a brighter future supported by innovative solutions and strategic mergers.

For further information on cultivate(MD) and their investment focus, visit cultivate-md.com. To learn more about Instrumentum and their services, check out instrumentum.com.